Predicted protein targets (top 4)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | SCN2A | Q99250 | 9/20 | 0.56 |
| ▸ | NPY5R | Q15761 | 7/20 | 0.56 |
| ▸ | HPGDS | O60760 | 3/20 | 0.50 |
| ▸ | MAP4K4 | O95819 | 2/20 | 0.47 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL6887923 | 0.94 | SCN2A (0.56) | SCN2ANPY5RHPGDSMAP4K4 | |
| SCHEMBL6885064 | 0.92 | SCN2A (0.59) | SCN2ANPY5RHPGDSMAP4K4 | |
| SCHEMBL6026939 | 0.84 | NPY5R (0.64) | SCN2ANPY5RHPGDS | |
| SCHEMBL4056971 | 0.80 | MASP2 (0.67) | SCN2AMAP4K4 | |
| Hydrochloric Acid SCHEMBL4053943 | 0.78 | MASP2 (0.65) | SCN2AMAP4K4 | |
| SCHEMBL7981198 | 0.77 | CYP2A6 (0.56) | NPY5RMAP4K4 | |
| SCHEMBL31614566 | 0.77 | SCN2A (0.73) | SCN2ANPY5RHPGDS | |
| SCHEMBL27723892 | 0.77 | SCN2A (0.59) | SCN2ANPY5RHPGDS | |
| SCHEMBL20812633 | 0.76 | KDM4E (0.50) | MAP4K4 | |
| SCHEMBL17283469 | 0.75 | SCN2A (0.96) | SCN2ANPY5RHPGDS |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-1613310-A1 | IMIDAZOLE DERIVATIVES FOR TREATMENT OF ALLERGIC AND HYPERPROLIFERATIVE DISORDERS | Avanir Pharmaceuticals (US) | 2006-01-11 | — | — | EP | disclosed |
| US-20040229927-A1 | Imidazole derivatives for treatment of allergic and hyperproliferative disorders | AVANIR PHARMACEUTICALS | 2004-11-18 | — | — | US | disclosed |
| WO-2004091610-A1 | IMIDAZOLE DERIVATIVES FOR TREATMENT OF ALLERGIC AND HYPERPROLIFERATIVE DISORDERS | AVANIR PHARMACEUTICALS (US) | 2004-10-28 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20040229927-A1 | Imidazole derivatives for treatment of allergic and hyperproliferative disorders | ICOS, TSLP, IKZF3 | SCN2A 4668/4885NPY5R 4342/4885HPGDS 69/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.